Silexion Therapeutics (SLXN US)

Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company developing proprietary RNA interference (RNAi) therapies for KRAS-driven cancers. The company is offering shares and warrants in a best-efforts offering to advance its pre-clinical and clinical studies and for general corporate purposes.